Stimulus, avaliação de tecnologia
Em relação à Saúde, o pacote de estímulos à economia dos EUA, prevê a dotação de $1.1 mil milhões destinada ao financiamento de estudos comparativos de avaliação de tratamentos com dispositivos médicos e medicamentos, cujo objectivo é determinar, entre as alternativas, quais os tratamentos mais efectivos.
Num país que gasta 16% do PIB em Saúde (2007), 25% em 2025 (estima-se), estes estudos são fundamentais para a eficiência da prescrição médica de medicamentos. link
Na configuração limite, devem ser afastados todos os tratamentos menos efectivos e simultaneamente mais caros que resultem de estudos comparativos.
Interessante o comentário seguinte sobre esta matéria.
Seems to me that there are some near term opportunities to get some drug cost out of the system without revolutionary changes in IT, and before we spend billions on more research into effectiveness. In our city, most of the major pharmacies each offer their own list of generics for $4.99 for 30 day's supply, and $9.99 for 90 day's supply. Additionally, the major carriers each have their formularies, noting how much the company, and how much the patient, pays for for a given drug. It would be a simple matter for my primary care doc to have these lists in his computer linked to my profile (e.g. formulary from my insurance, discount drug list from my pharmacy) so he can see the cost to me of various drug alternatives. He is then in a better position to recommend the most cost effective treatment for me, based on the effectiveness information he already has access to(though much of it may be anecdotal). At least he will be working the cost side of the equation to my benefit. HCPMR
Num país que gasta 16% do PIB em Saúde (2007), 25% em 2025 (estima-se), estes estudos são fundamentais para a eficiência da prescrição médica de medicamentos. link
Na configuração limite, devem ser afastados todos os tratamentos menos efectivos e simultaneamente mais caros que resultem de estudos comparativos.
Interessante o comentário seguinte sobre esta matéria.
Seems to me that there are some near term opportunities to get some drug cost out of the system without revolutionary changes in IT, and before we spend billions on more research into effectiveness. In our city, most of the major pharmacies each offer their own list of generics for $4.99 for 30 day's supply, and $9.99 for 90 day's supply. Additionally, the major carriers each have their formularies, noting how much the company, and how much the patient, pays for for a given drug. It would be a simple matter for my primary care doc to have these lists in his computer linked to my profile (e.g. formulary from my insurance, discount drug list from my pharmacy) so he can see the cost to me of various drug alternatives. He is then in a better position to recommend the most cost effective treatment for me, based on the effectiveness information he already has access to(though much of it may be anecdotal). At least he will be working the cost side of the equation to my benefit. HCPMR
Etiquetas: USA health
1 Comments:
We need comparative effectiveness research, or, I agree with Paul Krugman for the first time ever
I usually disagree with pretty much everything that liberal rock star Paul Krugman writes from his pedestal at the New York Times.
However, when it comes to comparative effectiveness research, link
I'm with him 100 percent. Physicians need an authoritative source of unbiased data, untainted by the influence of drug companies and device manufacturers.
With treatments and medications announced daily, having an entity definitively compare these newer, and often more expensive, options with established treatment regimens will be particularly useful in everyday practice.
The only way to tackle such a huge project is with money, and indeed, the Obama administration recognizes this fact by including $1.1 billion in comparative effectiveness research in the economic stimulus package.
Clearly, the pharmaceutical and device industry would like both the public and physicians to continue to assume that "newer means better." Not asking these questions allows them to continue promoting profit-making brand-name treatments.
Their motives in attempting to quash comparative effectiveness research could not be more obvious.
And for once, I concur with Mr. Krugman when he states, "This is truly vile."
MD
Enviar um comentário
<< Home